Image Credit: © Anna Averianova | stock.adobe.com

Journal of the American Veterinary Medical Association

 evaluated whether accelerometer‑based inertial measurement unit (IMU) sensors could identify racehorses at increased risk for fatal musculoskeletal injury (FMI). Investigators analyzed stride data from 28,481 starts by 11,834 Thoroughbreds at 10 US tracks from July 2021 to May 2024.

 Sensors (StrideSAFE) recorded 3‑axis acceleration at 800 Hz from a pocket in the saddle cloth; a machine‑learned algorithm then assigned each run a risk score (RS) from 1 (lowest) to 6 (highest).

Seventy‑four horses sustained an FMI within 120 days of scoring. Horses assigned a highest RS of 6 made up only 122 starts (0.4%) but were 44.6 times more likely to sustain an FMI than horses scored as 1. Approximately 4% (1 in 25) of horses with an RS of 6 incurred an FMI within 120 days. Fetlock fractures accounted for 65% of FMIs in the cohort, and every horse in the highest risk category that later suffered an FMI sustained a fetlock fracture.

 Although RS‑6 horses had a 44.6× higher 

 risk remained modest (~4% within 120 days). Many flagged horses will not have an FMI (false positives).

 Retrospective observational methods preclude causal inference; confounding and unmeasured management differences may influence outcomes.

 Tracks that adopt StrideSAFE may differ in surface, training, or management; external validity to other jurisdictions or populations is unproven.

 Thresholds for imaging, specific follow‑up protocols, cost, and access to advanced imaging are unresolved.

Multivariable analysis identified several associated factors. Intact males were more likely to receive higher risk scores than females. Shorter race distances were associated with higher RS assignments (the highest‑risk group had a mean race distance of approximately 1372 ± 237 m). The probability of FMI was lower on synthetic all‑weather surfaces compared with dirt and turf; dirt races comprised approximately 55% of starts in the data set.

Clinical relevance and practical workflow

Authors and the American Veterinary Medical Association frame the IMU‑plus‑algorithm system as a screening or triage tool rather than a diagnostic test.

 The system functions as a “check engine light,” enriching for horses that warrant expedited clinical evaluation, targeted lameness examination, and selective advanced imaging (eg, standing PET or targeted CT/MRI of the fetlock). Because RS‑6 assignments were rare (122 over approximately 145 weeks across 10 tracks, averaging < 1 RS‑6 case per week), concentrating advanced diagnostics on this small group is operationally feasible and could optimize use of limited veterinary resources.

IMU‑based monitoring with machine‑learned risk scoring can identify a tiny subset of Thoroughbreds at elevated relative risk of catastrophic musculoskeletal injury. Clinicians should interpret algorithmic risk scores alongside clinical exam and imaging, recognize the modest absolute risk among RS‑6 horses, and confirm funding and conflict‑of‑interest disclosures in the published manuscript prior to large‑scale adoption.

Mc Sweeney D, Wang Y, Palmer SE, et al. Thoroughbreds deemed to be most at risk by inertial measurement unit sensors suffered a fatal musculoskeletal injury at a higher rate than other racehorses. 

 Published online September 17, 2025. doi:10.2460/javma.25.04.0268

New technology could help reduce fatal injuries in horse races. News release. American Veterinary Medical Association. November 11, 2025. Accessed November 13, 2025. https://www.avma.org/news/press-releases/new-technology-could-help-reduce-fatal-injuries-horse-races

Articles

Inertial measurement unit sensors with machine‑learned risk scoring can flag a tiny group of Thoroughbreds at much higher risk of fatal musculoskeletal injury, enabling targeted clinical evaluation.

Biometric sensors may help identify the few Thoroughbreds at highest risk for fatal musculoskeletal injury

In this live podcast recording of The Vet Blast Podcast presented by dvm360, Adam Christman, DVM, MBA, and Heidi Lobprise, DVM, DACVD, share more insights onto the use of hyaluronic acid in periodontal therapy

The power of hyaluronic acid in periodontal therapy

, presented by dvm360, which was recorded live at Fetch National Harbor in Maryland, take a deep dive into the use of hyaluronic acid (HA) in veterinary dentistry with Heidi Lobprise, DVM, DAVDC. Learn why HA is an essential tool for enhancing tissue healing and regeneration in periodontal pockets and extraction sites, and even has emerging uses for stomatitis. Lobprise also explains to host Adam Christman, DVM, MBA, and listeners the mechanism of action, proper preparation, and why HA is a cost-effective, powerful addition to dental procedures.

Below is a partial transcript, edited lightly for clarity. 

: I want to know a little bit more about this, and so I can't think of anyone better than a boarded veterinary dentist to talk to us about this. So before we begin, let's actually talk about what [it is].

Hyaluronic acid. Now, since that's a little hard for me to say, I have trouble with my [letter R's], we're going to say 'HA' from now on. Is that OK? 

Okay, good. So the thing of it is, HA is a component of the extracellular matrix. So as you look at all cells, it knows this. It's natural to the cells. In addition, it's been used in many different forms, for injectable, topical, eye ulcers, you name it. It's really a good compound, because it lays a good groundwork to help with healing with endogenous cells. 

Fantastic. So what are some indications for it then?

In a dental disease, periodontal disease, anything that needs healing. So if I've done an extraction, it might help with those areas that I want to heal when I have periodontal pockets, and I've done some root planing, especially in those moderate pockets where I want to get the best tissue healing and regeneration. I'll use it in those pockets. I can also use it in extraction sites, and even with some regenerative types.

Nice. I do think of those extraction sites, because whenever…[we] generalists, when we do those dentals on the canines, and…we're like, "Oh, we have some of those deep holes that are in there." So I'm sure it would be great to have HA in there.

Podcasts

Discover innovative uses of hyaluronic acid in veterinary dentistry, enhancing healing and treatment.

Hyaluronic acid in periodontal treatment 

A specialty hospital, part of a North Carolina–based network of veterinary hospitals, is now offering internal medicine services. Additionally, Chewy Vet Care has opened a new facility in Aventura, Florida. Meanwhile, Dechra recently obtained a new certification status that will expand its education and training initiatives for its clients and workforce.

Points East Veterinary Specialty Hospital (Sims, North Carolina)

Points East Veterinary Specialty Hospital, which is part of Vets Pets' veterinary hospitals network, has expanded its specialty services to include an internal medicine service. The service will be led by Claire Wiley, VMD, DACVIM (SAIM). In addition to the new internal medicine offering, the hospital offers emergency, surgical, and critical care services. Providing those services are 2 boarded surgeons, 2 boarded criticalists, and 13 full-time emergency veterinarians.

Wiley obtained her veterinary degree and completed a rotating internship at the University of Pennsylvania. Later, she completed an internal medicine residency program at North Carolina State University College of Veterinary Medicine, where she did research on molecular diagnostics for early cancer detection and canine genetic diseases.

“Since its founding, Points East Veterinary Specialty Hospital has evolved to meet the growing needs of pets and referring veterinarians across Eastern North Carolina. The addition of internal medicine complements existing emergency, surgical, and critical care services, furthering the hospital's commitment to collaboration and patient-centered care,” Vets Pets wrote in a news release.

Chewy Vet Care Aventura (Aventura, Florida)

Chewy Vet Care Aventura. (Image courtesy of Chewy Vet Care)

Earlier this fall, Chewy Vet Care opened a new location in Aventura, Florida. The clinic features personalized room monitors that showcase patient photos, the care team, and appointment details during every appointment. Like other Chewy Vet Care centers, the Aventura facility was designed with the signature warm lighting and soft colors. The building also contains nonslip floors and pet-friendly materials for a calming environment. Other touches include Polaroid photos, selfie mirrors, and exam rooms named after patients.

“We are thrilled to bring Chewy Vet Care to Miami. It is an exciting moment for pet health care as more pet parents are embracing a lifestyle where their pets’ well-being is at the center of everything they do. Especially in Miami, where pets are part of the city’s vibrant culture, from morning beach walks to outdoor dining and community events,” said Mita Malhotra, MS, president of Chewy Health. “We look forward to delivering the personalized care and convenience that our customers have come to love and expect from Chewy, now a best-in-class veterinary practice."

Dechra becomes Human-Animal Bond Certified

Dechra recently announced it has become a Human-Animal Bond-Certified company. As part of its new status, the company has committed to supporting education on the human-animal bond for veterinary professionals and to supporting research efforts by the Human Animal Bond Research Institute (HABRI). Dechra said it will also train its workforce on the science of the human-animal bond.

Collectively, the North American Veterinary Community and HABRI offer the Human-Animal Bond Certification. The certification looks at the documented science behind the benefits of the human-animal bond and offers veterinarians tools to apply it in their practice through a series of virtual modules.

According to Dechra, the organization is helping make the certification an accessible and affordable continuing education online course for veterinarians and clinics. The company said it plans to offer training for the Human-Animal Bond Certification to its clients in early 2026.

Points East Veterinary Specialty Hospital adds internal medicine service led by Dr Claire Wiley. News release. Vets Pets. October 28, 2025. Accessed November 12, 2025. https://www.prnewswire.com/news-releases/points-east-veterinary-specialty-hospital-adds-internal-medicine-service-led-by-dr-claire-wiley-302597236.html 

Dechra advances public health as newest Human-Animal Bond Certified company. News release. Dechra. November 7, 2025. Accessed November 12, 2025. https://www.dechra.com/news/2025/november/habri-launch

The latest updates relating to animal care establishments and platforms.

Clinic center: Dechra becomes Human-Animal Bond–Certified company

Gallant, an animal health biotechnology company, announced earlier this week that it has made a massive advancement in the FDA conditional approval process for its lead therapy targeting refractory feline chronic gingivostomatitis (FCGS). According to the release, the FDA Center for Veterinary Medicine (FDA-CVM) issued a “Technical Section Complete letter for Target Animal Safety. By receiving this, the FDA determined that Gallant’s data support the 365-day safety requirement for stem cell therapy.

"Achieving TAS technical section completion means the successful demonstration of 365-day safety. Unlike most TAS studies conducted for pharmaceutical drugs in healthy animals, this study was conducted in client-owned cats with refractory FCGS, establishing both short- and long-term safety in this critical population. This represents another foundational milestone for Gallant's uterine-derived platform of allogeneic mesenchymal stromal cell therapies—and the potential first off-the-shelf cell therapy in veterinary medicine," said Valentine Williams, DVM, MS, DACVS, senior vice president of Clinical Development and Strategy at Gallant.

"With both reasonable expectation of effectiveness and target animal safety complete, the clinical relevance for conditional approval is established. We are moving rapidly into the next phase of launch planning to bring practitioners and pet parents a regenerative medicine solution for their loved ones, where before there was no hope. It's inspiring to see cats regain their quality of life after treatment with a product backed by proven safety. There is no greater career satisfaction."

The product currently under FDA review is Gallant’s sonruvetcel injectable suspension, a possible first-in-class uterine-derived allogenic mesenchymal stromal cell therapy (UMSC) for feline patients with refractory FCGS. The drug is sourced from healthy and specific-pathogen free feline donors that are FDA-qualified. The therapies are manufactured under current Good Manufacturing Practice (cGMP) conditions. Currently, the product is on track to receive FDA condition approval in early 2026.

The UMSC therapy for refractory FCGS received the “Technical Section Complete” for Reasonable Expectation of Effectiveness in September 2025.

"Safety is always our first and highest priority in developing new products for pets. The FDA's alignment on the 365-day safety data for sonruvetcel is not only validation for potentially the first off-the-shelf cell therapy in pets, but also validation for our entire platform of products in development," said Linda Black, DVM, PhD, CEO of Gallant. "We are one step closer to bringing a first-in-class therapy to veterinary medicine and a pipeline of products that target a pet's underlying disease, not just symptoms."

A study conducted by Gallant that recently was published in the

found that within the 46 cats in the study, 75% of the subjects that were treated demonstrated a clinically relevant improvement in their quality of life by day 0, almost half experienced measurable improvements in oral lesions, and all subjects had no serious treatment-related adverse events.

FDA Completes Safety for Gallant's First Ready-to-Use Stem Cell Therapy for Refractory FCGS. News release. Gallant. November 10, 2025. Accessed November 12, 2025. https://prnmedia.prnewswire.com/news-releases/fda-completes-safety-for-gallants-first-ready-to-use-stem-cell-therapy-for-refractory-fcgs-302610213.html

Williams V, Schneider JL, Parrish RS, et al. EXPRESS: Clinical field study evaluating the safety and efficacy of allogeneic uterine-derived mesenchymal stem cells for refractory feline chronic gingivostomatitis (FCGS). 

. 2025;0(ja). doi:10.1177/1098612X251385852

This completion is a crucial requirement in the approval process for a drug.

Gallant achieves drug approval milestone 

The American Heartworm Society (AHS) has elected a veterinary cardiologist to serve as its new president. Marisa Ames, DVM, DACVIM (Cardiology), associate professor of cardiology at the University of California, Davis School of Veterinary Medicine, was elected during the 2025 Triennial Heartworm Symposium in Fort Worth, Texas. Ames is the second veterinary cardiologist in AHS history to serve as the organization’s president.

Photo courtesy of the American Heartworm Society

Ames is a graduate of The Ohio State University College of Veterinary Medicine in Columbus. She completed internships at Michigan State University in East Lansing and Tufts University in Medford, Massachusetts, as well as a cardiology residency and postdoctoral fellowship at North Carolina State University (NC State) in Raleigh. She has served on the AHS board of directors since 2016 and was program cochair of the AHS Triennial Heartworm Symposia held in 2019, 2022, and 2025.

During Ames’s leadership term, AHS will be prioritizing several key efforts. These priorities include enlisting clinic participation in the AHS Heartworm Incidence Survey, which will be conducted in early 2026, and providing further insights and guidance for veterinary professionals on feline heartworm disease.

“Heartworm disease continues to be a serious challenge for the veterinary industry and the pet-owning public, despite advances in heartworm management protocols and product investments by the veterinary industry,” Ames said in a news release. “Given the prevalence of heartworm disease, it’s important that researchers continue to identify new drugs and find ways to repurpose existing ones for heartworm prevention and treatment.”

Ames succeeds immediate past president Jennifer Rizzo, DVM, founder of IntroVet, a continuing education provider for veterinary professionals. Rizzo will continue to serve on the AHS leadership team, according to the organization.

Additional AHS officers newly elected for the 2025-2028 term are as follows

Vice President Lisa Young, DVM, clinical leader in pet health parasiticides at Elanco, based in Indianapolis, Indiana

Secretary/Treasurer Uri Donnett, DVM, MS, DABVP (Shelter Medicine), lead veterinarian at the Dane County Humane Society in Madison, Wisconsin

Editor Lindsay Starkey, DVM, PhD, DACVM (Parasitology), associate professor of parasitology at the Oklahoma State University College of Veterinary Medicine in Stillwater

Research Chair Tom Nelson, DVM, medical director at the VCA Animal Medical Center of Northeast Alabama in Anniston

Symposium Program Chair Andrew Moorhead, DVM, MS, PhD, DACVM (Parasitology), associate professor at NC State College of Veterinary Medicine in Raleigh

Furthermore, 4 new members of the board of directors were elected at the symposium, and 3 previous members have rotated off the board. New board members include entomologist Lyric Bartholomay, PhD, from the University of Wisconsin-Madison; veterinary practitioners Autumn Brehm, DVM, medical director at Rowland Veterinary Services in New Tazewell, Tennessee; Cindy Culpepper, DVM, owner of Paws and Claws Animal Medical Center in Dunedin, Florida; and Julie Parks, DVM, a relief veterinarian from Long Beach, Mississippi; as well as veterinary technician representative Julie Legred, AAS, CVT, cofounder of Veterinary Advancements and Veterinary Education Program manager for Edcetera, from Bricelyn, Minnesota.

 Members rotating off the board include Chris Duke, DVM, co-owner of Bienville Animal Medical Center in Ocean Springs, Mississippi; Elizabeth Clyde, DVM, owner of Clyde’s Animal Clinic in Mattoon, Illinois; and Angele Bice, DVM, owner of Summerville Pet Clinic in South Carolina.

American Heartworm Association announces new leadership, priorities. News release. American Heartworm Association. November 12, 2025.

Officers. American Heartworm Society. Accessed November 12, 2025. 

https://www.heartwormsociety.org/about/executive-board

The organization elected new officers and board members during its 2025 Triennial Heartworm Symposium.

Veterinary cardiologist named president of the American Heartworm Society

This is the second part of a 2-article series with Martha Cline, DVM, DACVIM (Nutrition). While part 1 focused on how to use nutrition assessment to guide clinical diet selection, part 2 zeroes in on client education and practical feeding recommendations at diagnosis. 

Use nutrition assessment to guide diabetes care in dogs and cats

Editor’s note: This Q&A was drafted from an audio interview. The responses from Cline have been lightly edited for clarity and flow in a written format.

dvm360: What client-education strategies do you think about for diet adherence?

 These clients often need you to spend some time talking with them, and sometimes [it means] leveraging our support staff as well. Our vet technicians and nurses, a lot of them are capable of counseling owners as well, especially when it comes to the management of these cases. Specifically, from a nutrition perspective, it’s important to be very specific with our feeding recommendations. This means doing the calculation, telling an owner how much, how many times they should be feeding the pet, and what to expect. [Have a plan] if a pet isn’t finishing their meals or if they aren’t eating.

Sometimes these owners really need you to be very specific with them, especially when it comes to the nutrition part, because we know we’re already being specific with them on the insulin and that medical management side. But again, it can be really overwhelming. I don’t want to hand an owner a bag of food and just say, ‘follow what’s on the back of the label.’ I really want to make sure that we’re tailoring those specific feeding recommendations to the pet and to the owner, to make sure that we can get good compliance.

dvm360: How do you account for the household and real-world feeding challenges?

 It’s also really important to take into account the feeding management, because managing a diabetic dog or cat is a lot for an owner. It changes a lot of what happens daily in their household. So, we want to make sure we have a good idea of the environment and what the owner is able and capable of doing from a nutrition standpoint.

A good example would be a multi-pet or multi-cat household where we’re making specific recommendations for one cat; we really need to think about how to manage that household in a way that is actually going to be manageable from a feeding standpoint when we’re making such specific recommendations.

dvm360: What are common mistakes or missed opportunities you see in practice?

 I don’t necessarily want to call it a mistake, but maybe a missed opportunity is, again, to be very specific and tailored with your feeding recommendation. It’s going to help alleviate some of the work the owner has to do in figuring it out themselves, especially when they already feel overwhelmed. And it’s going to be more tailored specifically to that animal compared to making a generic recommendation.

So, taking the time to do the calculation and giving an owner a specific recommendation for food, how much to feed, and frequency, is really, really helpful. I do see that that doesn’t always happen, and I think that’s a missed opportunity for us in terms of managing these cases.

dvm360: Any practical tips about treats and owner expectations?

 Oh, and treat recommendations...we can’t forget that. You’re not going to be able to take treats away from everybody, but make sure that you’re accounting for them as well. Giving specific feeding recommendations and a specific medical recommendation has been shown to increase compliance in pet owners, so that’s another key thing.

dvm360: What resources or kits does Purina provide to clinics and how can they access them?

 At Purina, we provide a bag of the Purina DM for cats, or a bag of EN FiberBalance for dogs, as part of the kit when they are diagnosed with diabetes. Some of the other resources that we have...if people look at the Purina Institute website, we have calculators for helping to calculate how much to feed, and that can be really helpful.

We have maintenance energy requirement calculators that people can access, again, on Purina Institute center square, that can be really helpful in figuring out how much they need to feed these pets throughout the day. There are some other resources on there related to diabetic management as well that people can access from a clinical standpoint. So in addition to providing the food, we also have some nice resources online to help people in terms of figuring out how much [to feed] and ways to help guide the pet owner.

dvm360: How can clinics enroll or sign up?

 The website is usa.petdiabetesmonth.com. That’s where clinics can enroll. If they’re interested in participating, I would encourage them to visit that website for more information.

dvm360: If there’s one thing you want clinicians to remember about owner education, what is it?

 Take the time to give them a specific feeding recommendation, and that includes food, feeding amounts, and frequency.

Specific feeding instructions increase owner adherence and simplify diabetes management for dogs and cats.